Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”
November 24 2021 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company seeking to develop innovative medicines
in areas of significant unmet medical need with a current focus on
breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven
Quay, M.D., Ph.D., and Kyle Guse, GC & CFO will present at
Tribe Public’s Webinar Presentation and Q&A Event that is
scheduled to begin at 8am pacific/11am eastern on Tuesday, November
30th. During this complimentary event, Atossa management will
speak at a Q&A session focused on Atossa’s research programs
and future development. To join the complimentary event, please
register at ATOSQA.TribePublic.com. Once registered, Tribe members
may then send their questions for Atossa’s management to
research@tribepublic.com, which will be relayed during the event by
Tribe Public’s Managing Partner, John Heerdink.
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to develop innovative medicines in areas of
significant unmet medical need with a current focus on breast
cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
ABOUT TRIBE PUBLIC LLC
Tribe Public LLC is a San Francisco, CA based organization that
hosts complimentary worldwide webinar & meeting events in the
U.S. The Tribe’s complimentary events focus on issues that the
Tribe members care about with an emphasis on hosting management
teams from publicly traded companies from all sectors &
financial organizations that are seeking to increase awareness and
understanding of their products, progress and plans. Tribe members
primarily include Family Offices, Portfolio Managers, Registered
Investment Advisors, & Accredited Investors. Website:
http://www.tribepublic.com/
FORWARD-LOOKING STATEMENTS
Forward-looking statements in this press release and the Q&A
event, which Atossa undertakes no obligation to update, are subject
to risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including the risks and uncertainties associated with any variation
between interim and final clinical results, actions and inactions
by the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies of AT-H201,
AT-301 and Endoxifen, lower than anticipated rate of patient
enrollment, estimated market size of drugs under development, the
safety and efficacy of Atossa’s products, performance of clinical
research organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in breast density, Ki-67 or any other result from a
neoadjuvant study is an approvable endpoint for oral Endoxifen, and
other risks detailed from time to time in Atossa’s filings with the
Securities and Exchange Commission, including without limitation
its periodic reports on Form 10-K and 10-Q, each as amended and
supplemented from time to time.
Company Contact: Atossa Therapeutics, Inc. Kyle Guse, CFO and
General Counsel Office: (866) 893-4927 kyle.guse@atossainc.com
Investor Relations Contact: Core IR Office: (516) 222-2560
ir@atossainc.comSource: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024